Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 215 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Testim Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

NCT00104572
View directory record Official record
Conditions
Hypogonadism, Diabetes, Sarcopenia, Osteoporosis, Depression
Interventions
Androgel (Testosterone Gel), Anastrozole (Aromatase Inhibitor), Placebo tablet, Placebo gel, Calcium Cardone 500mg with vitamin D 400 IU
Drug · Dietary Supplement
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 4 Interventional

Natesto Spermatogenesis Reboot

NCT05381831
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
NatestoTM
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men

NCT00467870
View directory record Official record
Conditions
Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
Interventions
Testosterone Undecanoate 750 mg, Testosterone Undecanoate 1000 mg
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 28, 2026, 5:21 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair

NCT04345666
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Testosterone cypionate, Placebos
Drug
Lead sponsor
Orthopedic Institute, Sioux Falls, SD
Other
Eligibility
45 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 28, 2026, 5:21 AM EDT
Active, not recruiting Phase 1 Interventional

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

NCT06305598
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Bone Scan, Computed Tomography, Leuprolide Acetate, Magnetic Resonance Imaging, Survey Administration, Testosterone Cypionate
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 28, 2026, 5:21 AM EDT
Active, not recruiting Phase 1 Interventional

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

NCT04731376
View directory record Official record
Conditions
Hypogonadism, Malignant Urinary System Neoplasm, Urinary System Disorder, Urinary System Neoplasm
Interventions
Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate
Other · Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 28, 2026, 5:21 AM EDT
Recruiting Phase 2 Interventional

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

NCT06100705
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone Cypionate, Sipuleucel-T
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

NCT00587431
View directory record Official record
Conditions
Prostate Cancer
Interventions
GnRh (Leuprolide), Testosterone Gel, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes

NCT03973840
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Testosterone Undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Testosterone Undecanoate

NCT01765179
View directory record Official record
Conditions
Male Hypogonadism
Interventions
Oral testosterone undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 28, 2026, 5:21 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version

NCT07092527
View directory record Official record
Conditions
Transgenderism, Reproductive Issues
Interventions
Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

NCT04675788
View directory record Official record
Conditions
Long QT Syndrome, Abnormalities, Drug-Induced
Interventions
Progesterone, Ibutilide, Testosterone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
50 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 5:21 AM EDT
Recruiting Phase 2 Interventional

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

NCT04460872
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injury, Central Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male, Spinal Cord Trauma, Injuries, Spinal Cord, Walking, Difficulty, Gait Disorders, Neurologic, Locomotion Disorder, Neurologic, Wounds and Injuries, Nervous System Diseases, Testosterone Deficiency, Androgen Deficiency, Hormone Deficiency
Interventions
Testosterone Enanthate, Locomotor Training
Drug · Behavioral
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 28, 2026, 5:21 AM EDT
Not listed Phase 4 Interventional

A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel

NCT04976595
View directory record Official record
Conditions
Hypogonadism
Interventions
Natesto
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Testosterone Trials in Older Men

NCT00799617
View directory record Official record
Conditions
Andropause
Interventions
AndroGel® (testosterone gel), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 28, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women

NCT00141544
View directory record Official record
Conditions
Menopause
Interventions
esterified estrogens 1.25 mg and methyltestosterone 2.5 mg, Esterified estrogens 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
78
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2008 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

NCT00975650
View directory record Official record
Conditions
Hypogonadism
Interventions
Nasobol®, Androderm® (Positive Control)
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Tucson, Arizona • Burbank, California • Miami Gardens, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 28, 2026, 5:21 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents

NCT02679274
View directory record Official record
Conditions
Aging
Interventions
Placebo, Testosterone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Galveston, Texas • Texas City, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 28, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

Testosterone Plus Finasteride Treatment After Spinal Cord Injury

NCT02248701
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injuries, Central Nervous System Diseases, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions
Testosterone Enanthate, Finasteride, Placebo injection, Placebo pill
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 28, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

NCT00515112
View directory record Official record
Conditions
Prostate Cancer
Interventions
AndroGel, placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants

NCT04320745
View directory record Official record
Conditions
Hypogonadism
Interventions
Androderm®
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue

NCT00490555
View directory record Official record
Conditions
Healthy
Interventions
Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA), Placebo Testosterone gel, Placebo dutasteride, Placebo DMPA
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Oct 28, 2026, 5:21 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

NCT03518034
View directory record Official record
Conditions
Hypogonadism, Cardiovascular Diseases
Interventions
AndroGel®, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
5,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
379
States / cities
Alabaster, Alabama • Birmingham, Alabama • Decatur, Alabama + 262 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 28, 2026, 5:21 AM EDT